Company intelligence / Profile preview

InnoSIGN

Eindhoven, North Brabant, Netherlandsinnosignbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

InnoSIGN’s OncoSIGNal platform provides mRNA-based quantification of key cell signaling pathway activities to guide precision medicine decisions in oncology. The technology has demonstrated utility in predicting resistance to targeted therapies and informing treatment selection in breast and prostate cancers. It supports both clinical diagnostics and pharmaceutical research applications.

Recent results include prediction of resistance to AR-targeted drugs in metastatic castration-resistant prostate cancer and analysis of response/resistance patterns in breast cancer subtypes.

Therapeutic areas: OncologyOther
Modalities: mRNA-based diagnostics/testsPathway activity profiling (not a therapeutic modality but a diagnostic platform)
Industry: Molecular Diagnostics

Drug pipeline

1 asset

OncoSIGNal

Commercial

Indications: Cancer

Partnerships

Collaborations with biopharma companies via Scientist.com marketplace

Beyond the preview

Go deeper on InnoSIGN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InnoSIGN.

Explore the full profile